(Q80224586)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

main subject

phase II clinical trial

1 reference

inferred from title

hepatocellular carcinoma

1 reference

6

Margaret Tempero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Minaxi Jhawer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Lee Rosen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Janet Dancey

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Howard Hochster

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Solomon Hamburg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Neil Clendeninn

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Sridhar Mani

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

7 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

85-94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957834%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-006-9003-x

29 December 2019

exact match

0 references

cites work

How large should a phase II trial of a new drug be?

1 reference

12 December 2020

Chemotherapy studies in primary liver cancer. A prospective randomized clinical trial

1 reference

12 December 2020

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

1 reference

12 December 2020

Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors

1 reference

12 December 2020

Adriamycin therapy in American patients with hepatocellular carcinoma

1 reference

12 December 2020

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones

1 reference

12 December 2020

Hepatocellular carcinoma

1 reference

12 December 2020

Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake.

1 reference

12 December 2020

Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues

1 reference

12 December 2020

Survival probabilities (the Kaplan-Meier method).

1 reference

12 December 2020

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

1 reference

12 December 2020

Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group

1 reference

12 December 2020

Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous in

1 reference

12 December 2020

Hepatocellular carcinoma: the need for progress.

1 reference

12 December 2020

5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial

1 reference

12 December 2020

Chemotherapy for advanced hepatocellular carcinoma Adriamycin versus quadruple chemotherapy

1 reference

12 December 2020

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

1 reference

12 December 2020

Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer

1 reference

12 December 2020

AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies

1 reference

12 December 2020

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

12 December 2020

Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma

1 reference

12 December 2020

Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin

1 reference

12 December 2020